Reapplix Eyes US Market With Trial Results For Wound-Healing Tech
Executive Summary
Following the presentation of results from a randomized trial, Reapplix is ramping up its commercial operations with the hire of a new US president to lead sales of its wound-healing platform, LeucoPatch.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Abbott Surprises Analysts With CE Mark For Freestyle Libre 3
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.